-       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - April 2025
    -  200 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - April 2025
    -  200 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - April 2025
    -  200 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - April 2025
    -  200 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                 -       Report 
   - February 2025
    -  200 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                  -       Report 
   - October 2025
    -  148 Pages 
    Global
   
   From       €2291EUR$2,549USD£2,009GBP 
      €2696EUR$2,999USD£2,364GBP 
                  -       Report 
   - October 2025
    -  139 Pages 
    Global
   
   From       €2291EUR$2,549USD£2,009GBP 
      €2696EUR$2,999USD£2,364GBP 
                  -       Report 
   - September 2025
    -  149 Pages 
    Global
   
   From       €2291EUR$2,549USD£2,009GBP 
      €2696EUR$2,999USD£2,364GBP 
                  -       Report 
   - August 2025
    -  122 Pages 
    Global
   
   From       €2291EUR$2,549USD£2,009GBP 
      €2696EUR$2,999USD£2,364GBP 
                  -       Report 
   - August 2025
    -  140 Pages 
    Global
   
   From       €2291EUR$2,549USD£2,009GBP 
      €2696EUR$2,999USD£2,364GBP 
                  -       Report 
   - June 2025
    -  138 Pages 
    Global
   
   From       €2291EUR$2,549USD£2,009GBP 
      €2696EUR$2,999USD£2,364GBP 
                  -       Report 
   - April 2025
    -  147 Pages 
    Global
   
   From       €2291EUR$2,549USD£2,009GBP 
      €2696EUR$2,999USD£2,364GBP 
                  -       Report 
   - February 2025
    -  144 Pages 
    Global
   
   From       €2291EUR$2,549USD£2,009GBP 
      €2696EUR$2,999USD£2,364GBP 
                  -       Report 
   - February 2025
    -  145 Pages 
    Global
   
   From       €2291EUR$2,549USD£2,009GBP 
      €2696EUR$2,999USD£2,364GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - April 2025
    -  200 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - April 2025
    -  200 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - August 2025
    -  185 Pages 
    Global
   
   From       €4045EUR$4,500USD£3,547GBP 
                -       Report 
   - June 2025
    -  185 Pages 
    Global
   
   From       €4045EUR$4,500USD£3,547GBP 
             
         The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are    typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less   Read more